PCSK9 Forum
7th May 2015
Facebook Twitter RSS YouTube
For latest updates
Register today
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact

Latest news

New research
Combining high intensity statins and PCSK9 inhibitors

Many patients require high intensity statins which are known to upregulate PCSK9 expression.  But do they reduce the low density lipoprotein cholesterol (LDL-C) lowering effect of PCSK9 inhibitors?

A new analysis from the ODYSSEY trials shows that there was no evidence that the effectiveness of a PCSK9 inhibitor, alirocumab, was reduced by combining it with maximally-tolerated doses of a statin or another LDL-C lowering agent.

According to researchers, these findings confirm that PCSK9 inhibitors will be clinically valuable in high cardiovascular (CV) risk patients who fail to attain LDL-C goal with currently available treatments including statins.

Read the full report

High cholesterol: An unmet need   Lowering LDL-C: How low and for how long?   Residual cardiovascular risk: A role for PCSK9

When statins cause muscle symptoms

A consensus panel of the European Atherosclerosis Society has published a statement on the muscle symptoms associated with statins, which can result in withdrawal of treatment or non-adherence with therapy.

The panel highlights this issue at a time when recent clinical trials with a novel PCSK9 inhibitor, alirocumab, demonstrate that it can be used successfully in up to 90% of patients who initially reported that they could not tolerate statins.

Read the full report

Download the EAS Consensus Panel Report

Expert comments on consensus statement

Familial hypercholesterolaemia - Challenge for the next decade

Today, people with familial hypercholesterolaemia (FH) are:

  • Poorly identified
  • Under-treated

Dr Kees Hovingh, of the Academic Medical Centre, Amsterdam, calls for a collaborative strategy to address this common inherited condition.  To achieve success the strategies must recognise the need for education; understanding of patient power; and, improved treatment.

Read the full report

Listen to Dr Hovingh discuss the challenges

Treating FH in Latin America – The issues

FH in Argentina (Spanish)   FH in Brazil (Portuguese)

Use the stairs - lower PCSK9 expression?

Experimental studies suggest that increased physical activity reduces PCSK9 expression as well as lowering LDL-C and triglycerides and raising high density lipoprotein cholesterol (HDL-C).

A study demonstrated that healthy volunteers who used stairs for three months rather than elevators experienced a 20% decrease in serum PCSK9 levels.

Read the full report

Send an invitation to join PCSK9 Forum to your colleagues »
PCSK9 Education and Research Forum

Invotation from John Chapman
Aims & Objectives video
Read our Mission Statement
Partnership and outreach
Meet our Editorial Board
View Forthcoming Meetings
  Follow us on Twitter
For the latest updates on the hot topics, PCSK9 news and conference reports.
Most Viewed Videos

Will PCSK9 monoclonal antibodies replace other lipid lowering treatment?
Frederick Raal

The role of PCSK9 inhibitors in familial hypercholesterolaemia (FH)
Dirk Blom

What are the gaps in knowledge about the PCSK9 inhibitors?
Evan Stein

Implications from TESLA and early TAUSSIG studies with evolocumab
Gerald Watts

ODYSSEY trials at ESC Congress Hotline
Alberto Zambon

View our YouTube channel »
See more on pcsk9forum.org
Send to a colleague »

Coming soon reports from:
ISA 2015 17th International Symposium on Atherosclerosis
23-26 May 2015, Amsterdam, The Netherlands
  Supported by educational grants from: Amgen Lilly pFizer Sanofi  
Copyright PCSK9 Forum 2015. Please click here to unsubscribe from future mailings.